The MLKL-mRNA-based therapy described here resulted in the clear induction of tumor antigen-specific CD4+ and CD8+ T cell responses without a necessity for tumor sequencing, epitope prediction, and production of a personalized vaccine vector (Fig. 6e, f). Here, CD8A is linked to neoplasm.